Efficacy of Activator Trigger Point and Shock Wave Therapy on Pain and Function in Active Upper Trapezius Trigger Points: A Randomized Controlled Study

NCT07594223 · tracked via the Priya Life Science Egypt tracker

Sponsor

Cairo University

Phase

Not applicable

Started

2026-07-01

Last updated

2026-05-18

Condition(s) studied

Cervical

Investigational drug(s) / intervention(s)

ShockwaveActivator

Shockwave: will receive extracorporeal shock wave therapy applied to the same region. 12. The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period.

Activator: will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle.

Study summary

This study will be conducted as a randomized controlled trial to evaluate the efficacy of trigger point activator and extracorporeal shock wave therapy in patients with active myofascial trigger points in the upper fibers of the trapezius muscle. Participants who meet the inclusion criteria will be recruited and informed consent will be obtained prior to participation. The subjects will then be randomly allocated into two equal groups. Group A: will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle. Group B: will receive extracorporeal shock wave therapy applied to the same region.

The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period. Outcome measures will be assessed before the beginning of the treatment program and after completion of the intervention period. Pain intensity and pressure pain threshold will be assessed using an algometer. Functional disability related to the neck will be evaluated using the Neck Disability Index (NDI). All collected data will be recorded and statistically analyzed to determine the effectiveness of both treatment modalities in reducing pain and improving functional outcomes.

Eligibility

Sex

ALL

Min age

27 Years

Max age

40 Years

Healthy volunteers

Inclusion Criteria: * 1\. Male or female participants aged between 25 and 40 years. 2. Body Mass Index (BMI) between 20 and 30 kg/m². 3.Presence of active myofascial trigger points in the upper fibers of the trapezius muscle confirmed by clinical examination. * Complaints of neck pain associated with upper trapezius trigger points. 5. Ability and willingness to participate in the treatment sessions and follow the study protocol. Exclusion Criteria: * 1\. History of neck trauma, cervical spine fracture, or cervical spine surgery. 2. Presence of neurological disorders affecting the cervical region. 3. Presence of cervical disc prolapse or severe cervical spine pathology. 4. Diagnosis of fibromyalgia or systemic musculoskeletal disorders. 5. Presence of skin diseases, wounds, or infections at the treatment area. 6. Patients with malignancy or severe systemic diseases.

Primary outcome measure(s)

Neck Disability Index (NDI) — 6 weeks
Questionnaire assessing neck function valid and reilable
VAS — 6 weeks
Pain score

Trial sites (1)

Facility	City	Region	Status
Suez Uni	Suez	Egypt

More Cairo University trials in Egypt

Effect of High Power Laser Acupuncture on Post Menopausal Hot Flashes Starting soon

Brochoscopic Intervention Versus Conventional Management in Acute Lung Collapse in the Pediatric Intensive Care Unit Active, not recruiting

Effect of Neuromuscular Electrical Stimulation on Muscle Mass in ECMO Patients Starting soon

Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery Active, not recruiting

SHAPE Versus Milligan-Morgan Hemorrhoidectomy for Hemorrhoidal Disease Recruiting

Other trials for the same condition

Cervical Erector Spinae Plane Block in Proximal Humeral Fracture Surgery, A Motor-Sparing Block Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07594223 on ClinicalTrials.gov ↗ ← All trials in Egypt